Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
National Healthcare Disparities Report, 2005

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Management: PCP and MAC Prophylaxis

Management of chronic HIV disease includes outpatient and inpatient services. Because national data on HIV care are not routinely collected, HIV measures tracked in the NHDR come from the HIV Research Network, which consists of 18 medical practices across the United States that treat large numbers of HIV patients. Although program data are collected from all Ryan White CARE Act grantees, the aggregate nature of the data make it difficult to assess the quality of care provided by Ryan White CARE Act providers. As HIV disease progresses, CD4 cell counts fall and patients become increasingly susceptible to opportunistic infections. When CD4 cell counts fall below 200, medicine to prevent development of Pneumocystis pneumonia (PCP) is routinely recommended; when CD4 cell counts fall below 50, medicine to prevent development of disseminated Mycobacterium avium complex (MAC) infection is routinely recommended.29

Figure 2.12. HIV patients with CD4 cell count <200 who received PCP prophylaxis in the past year, by race/ethnicity, 2002

Figure 2.12. HIV patients with CD4 cell count <200 who received PCP prophylaxis in the past year, by race/ethnicity, 2002

[D] Select for Full Text Description.

Source: HIV Research Network, 2002.

Reference population: HIV patients age 18 and older receiving care from HIV Research Network providers.

Note: Whites and Blacks are non-Hispanic populations.

  • The proportion of HIV patients with CD4 cell count <200 who received PCP prophylaxis did not differ significantly by race/ethnicity (Figure 2.12).

Figure 2.13. HIV patients with CD4 cell count <50 who received MAC prophylaxis in the past year, by race/ethnicity, 2002

Figure 2.13. HIV patients with CD4 cell count <50 who received MAC prophylaxis in the past year, by race/ethnicity, 2002

[D] Select for Full Text Description.

Source: HIV Research Network, 2002.

Reference population: HIV patients age 18 and older receiving care from HIV Research Network providers.

Note: Whites and Blacks are non-Hispanic populations.

  • The proportion of HIV patients with CD4 cell count <50 who received MAC prophylaxis did not differ significantly by race/ethnicity (Figure 2.13).

 

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care